These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 21706943

  • 1. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W, Lueangniyomkul A, Manosuthi W.
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [Abstract] [Full Text] [Related]

  • 2. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    Sathia L, Obiorah I, Taylor G, Kon O, O'Donoghue M, Gibbins S, Walsh J, Winston A.
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R.
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [Abstract] [Full Text] [Related]

  • 5. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzold D, Hartmann M.
    Eur J Med Res; 2008 Jul 28; 13(7):343-8. PubMed ID: 18700192
    [Abstract] [Full Text] [Related]

  • 6. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W, Luaengniyomkul A, Manosuthi W.
    J Med Assoc Thai; 2012 Feb 28; 95(2):163-9. PubMed ID: 22435244
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.
    Moses M, Zachariah R, Tayler-Smith K, Misinde D, Foncha C, Manzi M, Bauerfeind A, Mwagomba B, Kwanjana J, Harries AD.
    Int J Tuberc Lung Dis; 2010 Feb 28; 14(2):197-202. PubMed ID: 20074411
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC.
    PLoS One; 2017 Feb 28; 12(2):e0171596. PubMed ID: 28222098
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Patel A, Patel K, Patel J, Shah N, Patel B, Rani S.
    J Acquir Immune Defic Syndr; 2004 Sep 01; 37(1):1166-9. PubMed ID: 15319677
    [Abstract] [Full Text] [Related]

  • 17. Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis.
    Villar J, Sánchez P, González A, Sorli L, Montero MM, Guelar A, Solé E, López JL, Knobel H.
    HIV Clin Trials; 2011 Sep 01; 12(3):171-4. PubMed ID: 21684857
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C.
    Trials; 2020 Feb 13; 21(1):181. PubMed ID: 32054536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.